Title:Non-coding RNAs in Regulation of Protein Aggregation and Clearance
Pathways: Current Perspectives Towards Alzheimer's Research and
Therapy
Volume: 24
Issue: 1
Author(s): Sonali Sundram, Neerupma Dhiman*, Rishabha Malviya and Rajendra Awasthi*
Affiliation:
- Amity Institute of Pharmacy, Amity University Uttar Pradesh, Noida, India
- Department of Pharmaceutical Sciences, School
of Health Sciences & Technology, UPES University, Dehradun, Uttarakhand, India
Keywords:
Alzheimer's disease, dementia, neurodegenerative disorder, tau protein, Non-coding RNAs, motor skills impairment.
Abstract: Alzheimer's disease (AD) is the leading cause of dementia, affecting approximately 45.0
million people worldwide and ranking as the fifth leading cause of mortality. AD is identified by neurofibrillary
tangles (NFTs), which include abnormally phosphorylated tau-protein and amyloid protein
(amyloid plaques). Peptide dysregulation is caused by an imbalance between the production and clearance
of the amyloid-beta (Aβ) and NFT. AD begins to develop when these peptides are not cleared
from the body. As a result, understanding the processes that control both normal and pathological protein
recycling in neuronal cells is critical. Insufficient Aβ and NFT clearance are important factors in
the development of AD. Autophagy, lysosomal dysfunction, and ubiquitin-proteasome dysfunction
have potential roles in the pathogenesis of many neurodegenerative disorders, particularly in AD.
Modulation of these pathways may provide a novel treatment strategy for AD. Non-coding RNAs
(ncRNAs) have recently emerged as important biological regulators, with particular relevance to the
emergence and development of neurodegenerative disorders such as AD. ncRNAs can be used as potential
therapeutic targets and diagnostic biomarkers due to their critical regulatory functions in several
biological processes involved in disease development, such as the aggregation and accumulation of
Aβ and NFT. It is evident that ncRNAs play a role in the pathophysiology of AD. In this communication,
we explored the link between ncRNAs and AD and their regulatory mechanisms that may help in
finding new therapeutic targets and AD medications.
